Ignite Creation Date:
2024-06-16 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06423859
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2024-05-16
Brief Title:
Articaine Plus Dexmedetomidine in Supraclavicular Block
Sponsor:
Benha University
Organization:
Benha University
Study Overview
Official Title:
A Comparative Study Between Articaine Alone Versus Articaine Plus Dexmedetomidine for Ambulatory Orthopedic Surgery Under Supraclavicular Block
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Articaine has emerged as a local anesthetic LA that produces sensory and motor blockade shorter than bupivacaine and lower in neurotoxicity than lidocaine
Studies have shown that adding dexmedetomidine to LA produces prolongation of sensory and motor bock duration
Early regain of motor power with adequate analgesia is needed in ambulatory surgery for early start of physiotherapy This study was designed to test efficacy of adding dexmedetomidine to articaine on the duration of sensory and motor block
Studies have shown that adding dexmedetomidine to LA produces prolongation of sensory and motor bock duration
Early regain of motor power with adequate analgesia is needed in ambulatory surgery for early start of physiotherapy This study was designed to test efficacy of adding dexmedetomidine to articaine on the duration of sensory and motor block
Detailed Description:
Articaine is an amide LA produced in the 1960s and first used in clinical trials in 1974 Although it is an amide that is similar to prilocaine in chemical structure it contains a thiophene ring rather than a benzene ring Articaine is a rapid and short acting LA which has low neurotoxicity and appears to diffuse through tissues more readily than other commonly used LA agents It is metabolized by nonspecific plasma esterases both in blood and tissues leading to its rapid clearance
α2-adrenergic receptor agonists have been the focus of interest for their sedative analgesic perioperative sympatholytic and cardiovascular stabilizing effects along with providing reduction in anesthetic requirements Dexmedetomidine may act on supraspinal locus coeruleus or spinal level or peripheral α2-adrenoreceptor to reduce nociceptive transmission leading to analgesia
Previous trials focused on adding dexmedetomidine to either levobupivacaine and bupivacaine found augmentation of both sensory and motor block along with prolonged duration of effective analgesia However there remains limited knowledge of the analgesic efficacy and clinical utility of adding dexmedetomidine to articaine during peripheral nerve block in humans
α2-adrenergic receptor agonists have been the focus of interest for their sedative analgesic perioperative sympatholytic and cardiovascular stabilizing effects along with providing reduction in anesthetic requirements Dexmedetomidine may act on supraspinal locus coeruleus or spinal level or peripheral α2-adrenoreceptor to reduce nociceptive transmission leading to analgesia
Previous trials focused on adding dexmedetomidine to either levobupivacaine and bupivacaine found augmentation of both sensory and motor block along with prolonged duration of effective analgesia However there remains limited knowledge of the analgesic efficacy and clinical utility of adding dexmedetomidine to articaine during peripheral nerve block in humans
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None